
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is a promising company with a strong pipeline of innovative oncology drugs and a successful and in-demand covid vaccine. Financially, the company is projected to have a firm value of $33B and has potential for future partnerships and market uptake. While risks do exist, BioNTech's advancements in the field of immunotherapy and its positive clinical trial data make it a strong investment opportunity with a potential upside reflected in the price target of $130 per share.
Bears say
BioNTech is facing several key risks, including: (1) competition from other biotech companies with similar products or pipelines; (2) potential failure of their cancer therapeutics and vaccines in clinical trials; (3) failure to advance their other programs in a timely manner, leading to possible commercial and regulatory risks and long-term dilution for investors. Additionally, their partnerships and potential for mergers and acquisitions may bring about its own set of risks.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares